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Abstract: According to the WHO, 38 million individuals were living with human immunodeficiency
virus (HIV), 25.4 million of which were using antiretroviral therapy (ART) at the end of 2019. Despite
ART-mediated suppression of viral replication, ART is not a cure and is associated with viral persistence, residual inflammation, and metabolic disturbances. Indeed, due to the presence of viral
reservoirs, lifelong ART therapy is required to control viremia and prevent disease progression into
acquired immune deficiency syndrome (AIDS). Successful ART treatment allows people living with
HIV (PLHIV) to achieve a similar life expectancy to uninfected individuals. However, recent studies
have illustrated the presence of increased comorbidities, such as accelerated, premature immune
aging, in ART-controlled PLHIV compared to uninfected individuals. Studies suggest that both
HIV-infection and ART-treatment lead to mitochondrial dysfunction, ultimately resulting in cellular
exhaustion, senescence, and apoptosis. Since mitochondria are essential cellular organelles for energy
homeostasis and cellular metabolism, their compromise leads to decreased oxidative phosphorylation (OXPHOS), ATP synthesis, gluconeogenesis, and beta-oxidation, abnormal cell homeostasis,
increased oxidative stress, depolarization of the mitochondrial membrane potential, and upregulation
of mitochondrial DNA mutations and cellular apoptosis. The progressive mitochondrial damage
induced by HIV-infection and ART-treatment likely contributes to accelerated aging, senescence,
and cellular dysfunction in PLHIV. This review discusses the connections between mitochondrial
compromise and cellular dysfunction associated with HIV- and ART-induced toxicities, providing
new insights into how HIV and current ART directly impact mitochondrial functions and contribute
to cellular senescence and aging in PLHIV. Identifying this nexus and potential mechanisms may be
beneficial in developing improved therapeutics for treating PLHIV.
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1. Introduction
1.1. Human Immunodeficiency Virus (HIV)
HIV is a lentivirus of the Retroviridae family, infecting humans worldwide. The
HIV lifecycle has seven major steps: binding, fusion, reverse transcription, integration,
replication, assembly, and budding (Figure 1) [1–8]. The mechanism of HIV infection is
best described as an opportunistic, strategic manipulation of host cells, inducing immense
deregulation on the human immune system, including intrinsic, innate, and adaptive immunity, as well as on many nonimmune cells and tissues [6]. HIV infection is characterized
by a progressive weakening of the immune system, induced by a significant depletion
of CD4 T cells. Two main factors contribute to the loss of CD4 T lymphocytes: (1) the
aberrant inflammatory response induced by HIV infection; and (2) viral pathogenesis—HIV
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uses cells for viral integration, replication, and release [7–9]. HIV infection also induces a
significant upregulation of proinflammatory cytokines, further contributing to the viral
pathogenesis [10–13].

Figure 1. The viral lifecycle of human immunodeficiency virus HIV-1 infection and steps of antiretroviral therapy (ART)
interference. HIV infection begins by glycoproteins, such as Env/gp120, on the surface of the HIV virus interacting with CD4
and CCR5/CXCR4 receptors on the surface of a target CD4 T cell (step 1), which is inhibited by coreceptor antagonists. This
facilitates fusion between the HIV membrane and the cell membrane (step 2). This step is inhibited by fusion inhibitors. The
viral capsids containing HIV enzymes and viral RNA are released into the cell cytoplasm, followed by reverse transcription
of the viral RNA into DNA by HIV reverse transcriptase (step 3), which is inhibited by nucleoside-analog and non-nucleoside
reverse transcriptase inhibitors (NRTIs and NNRTIs). The viral DNA is then transported into the cell nucleus for integration
into the host genome by HIV integrase and transcription (steps 5 and 6). Integrase inhibitors, including INIs and INSTIs,
prevent the integration step. The transcribed DNA is then released into the cytoplasm for translation via Rev-mediated
export (step 7) and assembly into the viral capsid (step 8) for budding (step 9) and release (step 10), following which HIV
protease cleaves polyproteins to create an active virus capable of infecting new cells. Protease inhibitors prevent the final
release of a functional replicating virus.

One of the major difficulties in curing HIV is reservoir formation and viral latency.
Latency is a reversible quiescent state during which the virus survives in host cells but
does not replicate, concealing itself in reservoirs through which it can later become reactivated [14]. HIV infects target cells, including but not limited to CD4 T cells, macrophages,
and lymphoid tissues, and integrates proviral DNA into the host genome to establish
reservoirs. Antiretroviral therapy (ART) allows for virological control of HIV replication
and prevents CD4 T cell numbers from falling below the threshold (200 cells/µL) associated
with severe immune deficiency; however, ART cessation readily allows for activation of
reservoir-residing cells and the production of actively replicating HIV [11,15–18].
The current leading form of treatment for HIV is a form of combined ART therapy,
termed highly active antiretroviral therapy (HAART) [19,20]. During the initial development of ART, treatments were used in a monotherapy form; however, the increased
incidence of drug resistance led to the use of combination therapy to minimize morbidity
and mortality of HIV-infection and efficiently control viral replication [21]. ART is highly
successful in reducing actively replicating virus; however, due to the presence of HIV
reservoirs and incomplete elimination of virus, once ART is stopped, viremia rises to levels
similar to those observed prior to ART treatment [22]. No currently available treatment
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successfully clears integrated proviral DNA incorporated in the host genome [15,23–25].
Thus, PLHIV must maintain strict lifelong treatment adherence in order to prevent viral
rebound [26]. Additionally, despite ART-mediated viral suppression aiding CD4 T cell
recovery, this reversal constitutes an incomplete immune reconstitution, forcing PLHIV to
face lifelong challenges with immune failure [27,28].
1.2. Mitochondria Function in Cellular Energetics and Homeostasis
Mitochondria are organelles present in almost all eukaryotic cells and provide energy
to the cell in order to maintain normal cellular functions and homeostasis [29]. Mitochondria complete oxidative phosphorylation (OXPHOS) to form ATP via mitochondrial
respiration through electron transport chain (ETC)-mediated production of an electrochemical gradient across the inner mitochondrial membrane, termed the mitochondrial
membrane potential (∆Ψm ). The presence of this gradient enables ATP synthase to recycle
the protons from the gradient to facilitate the energetically unfavorable production of
ATP [30–33]. Any slight disruption to the ∆Ψm has large consequences for the levels of
cellular respiration and ATP synthesis.
Mitochondria are also involved in apoptosis signaling pathways and calcium signaling and storage. Mitochondria are integral to both intrinsic and extrinsic cell death
pathways through several signaling molecules, including cytochrome c and caspases [34].
Additionally, mitochondria are essential in the regulation of cellular metabolism, immune
signaling, cell differentiation, and maintenance of the cell cycle and cell growth, all of
which contribute to mitochondrial biogenesis and the fine balance between mitochondrial
fusion, fission, and morphology [32,35,36]. Mitochondrial morphology and function have
been shown to become disrupted in several disease states. Deregulation of mitochondrial function leads to increased reactive oxygen species (ROS), which are involved in
cell signaling but also induce toxicity and DNA damage [29,35]. Increased ROS production due to deregulated ETC activity leads to the upregulation of uncoupling proteins
and protein leakage through the adenine nucleotide translocator. These phenomena lead
to the uncoupling of mitochondrial-mediated respiration and ATP synthesis, increasing
mitochondrial oxygen consumption and fatty acid oxidation. Despite increased oxygen
consumption, ATP synthesis is limited, resulting in ATP deficiency and deregulated cellular
metabolism [36,37].
Mitochondria have an independent circular DNA composed of ~16 kilobases. While
the majority of the genes encoding for proteins required for mitochondrial function are
encoded in the nuclear genome and their proteins are transported into the mitochondria,
mitochondrially encoded genes are essential for mitochondrial functions. Specifically, mitochondrial DNA (mtDNA) encodes for crucial components of the ETC and mitochondrial
biogenesis. Mutations and deletions of mtDNA, which can be caused by ROS, lead to adverse effects on mitochondrial function [38–40]. This process may contribute to aging and
the gradual loss of vigor in aged populations [41,42]. For example, mitochondrial deregulation leads to leakage of high-energy electrons in the respiratory chain, creating ROS.
Increased oxidative stress leads to drastic increases in DNA mutations or deletions, creating
a cycle of mitochondrial deregulation, increased oxidative stress, and mtDNA damage.
Nuclear DNA repair pathways, such as base excision repair and double-strand break repair,
can repair damaged mtDNA through nuclear-encoded genes; however, these processes
may be deregulated during HIV-infection. For instance, emerging work from our group
and others have shown dysregulation of critical DNA damage response proteins, such as
ATM, ATR, DNA-PKcs, TOP I/IIα, and p53 in the setting of HIV-infection [39,43–48]. The
literature shows that mitochondrial function and signaling pathways become disrupted in
the presence of HIV-infection and ART treatment.
1.3. ART-Suppressed HIV and Mitochondrial Dysfunction in Cellular Senescence and Aging
Recently, several works have classified multiple physiological characteristics as hallmarks of aging, including genomic instability, telomere attrition, mitochondrial dysfunc-
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tion, reduced proliferative capacity, altered intracellular communication, aberrant inflammation, and cellular senescence (the quiescent, nonreplicative state in which cells are
functionally anergic), all of which are commonly observed in PLHIV [49–51]. Telomere
erosion, along with telomeric DNA damage, has been deemed a molecular clock of cellular
aging. Telomeric DNA damage activates p53, leading to cellular growth arrest, apoptosis, and senescence [52]. In addition, a study examining ART-treated, aviremic PLHIV
identified a correlation between shortened telomere length and poor immunologic recovery [53]. Interestingly, recent studies suggest that senescent cells secrete mediators that
can induce mitochondrial dysfunction in bystander neighboring cells, leading to increased
ROS production and DNA damage to induce senescence in the form of senescence-induced
senescence rather than replicative senescence [54–56]. Senescence has also lately been
identified as a potential antiviral defense mechanism to aid in activating the immune
system to clear the infection. However, prolonged exposure to cellular damage that occurs
during HIV infection leads to an increase in cellular senescence, which ultimately leads to
an accumulation of chronic inflammation and immune failure [57,58]. Each of these factors
ultimately contributes to increased incidence of age-related comorbidities, such as neurodegenerative, cardiovascular, and metabolic diseases, and cancers, in PLHIV [51,53,59–61].
In addition to HIV-accelerated premature aging, ART-treatment may also contribute
to mitochondria-related aging. While early ART initiation and strict ART adherence have
been shown to reduce the risk of PLHIV developing comorbidities, immune phenotyping
has also revealed that even in cases of long-term ART-treated individuals still demonstrate
abnormal cellular functions, homeostasis, and cell activation status, implying the possibility
that ART may further contribute to the HIV-accelerated premature aging [51,61]. Specifically, ART has been shown to induce low-grade inflammation, mitochondrial dysfunction,
and senescence in various cell types, even after relatively short-time exposure [62]. These
data highlight the need for further investigation into HIV- and ART-induced mitochondrial
compromise and inflammaging (inflammation-induced aging).
2. Current Outlook
Considering the number of essential processes mitochondria are involved in, any
influence from external stimuli, such as HIV infection or ART treatment, may have a
detrimental effect on mitochondrial activity. The deregulation of mitochondrial function
has several downstream effects, many of which are critical to cellular function and survival.
The current leading measures of mitochondrial functions include evaluation of mtDNA
copy number, mtDNA mutations, ROS generation, ∆Ψm , cellular respiration, apoptosis,
and ATP production. These parameters can be used to assess both the metabolic and
genomic status of cells following potential drug and HIV toxicity. There is a current lack of
understanding of how ART treatments and HIV individually and potentially cooperatively
lead to mitochondrial dysfunction, as well as how these processes likely contribute to the
progressive immune aging observed in PLHIV on ART.
2.1. HIV-Induced Mitochondrial Dysfunction: The Influence of Virally Encoded Proteins
HIV infection has been shown to induce differential regulation of mitochondrial
activity in various cell types. For instance, studies have shown that ∆Ψm is reduced
in HIV-infected, ART-naïve patients compared to HIV-negative healthy subjects, and a
negative correlation between ∆Ψm and the percentage of apoptotic lymphocytes. CD4+ T
cell numbers have been shown to be positively correlated to the change in ∆Ψm in HIVinfected, ART-naïve individuals [63,64]. It is likely that mitochondrial deregulation partially
arises from the activities of virally encoded proteins. HIV-1 encodes several proteins critical
for viral replication and integration, including viral structural proteins Gag, Pol, and Env,
essential regulatory elements Tat and Rev, and accessory regulatory proteins Nef, Vpr,
Vif, and Vpu. Literature shows that several of these virally encoded proteins, including
Env, Vpr, Tat, Nef, and Vpu, contribute to HIV-induced cell apoptosis, which is mediated
by mitochondrial activity [65–67]. Each of these proteins can cause bystander-induced
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Figure 2. Model of cooperative induction of mitochondrial compromise by HIV-infection and ART-treatment. Mitochondrial
Figure 2. Model of cooperative induction of mitochondrial compromise by HIV-infection and ART-treatment. Mitochondysfunction is mediated by viral integration, disruption of mitochondrial membrane potential (∆Ψm), decreased respiration
drial dysfunction is mediated by viral integration, disruption of mitochondrial membrane potential (ΔΨm), decreased
and ATP synthesis, mtDNA mutations, impaired mtDNA repair, intrinsic apoptosis, and oxidative stress. Collectively, these
respiration and ATP synthesis, mtDNA mutations, impaired mtDNA repair, intrinsic apoptosis, and oxidative stress. Colderegulations
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In addition to facilitating infection via interactions with coreceptors and the glycoIn addition to facilitating infection via interactions with coreceptors and the glycoproteins present on the virion surface, Env is also critical for interaction with uninfected
proteins present on the virion surface, Env is also critical for interaction with uninfected
neighboring cells via its localization in the cell membrane of an infected cell and interaction
with neighboring cell surface receptors (see Figure 2) [70,71]. Thus, the connection between
bystander-induced apoptosis and cells presenting virally encoded proteins may provide
key insights into the mechanism by which HIV-infection leads to diminished numbers of
CD4+ T cells and premature immune aging [71–73].
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2.3. HIV-Encoded Vpr: A Regulator of Apoptosis and Mitochondrial Function
In addition to mitochondrial deregulation induced by virally-encoded Env, Vpr is also
capable of eliciting HIV-induced apoptosis. Vpr is an accessory protein that is essential
to the progression of viral integration via facilitating transportation of the preintegration
complex into the host cell nucleus to allow for the incorporation of the viral genome into
host DNA [74,75]. The ability of the Vpr gene product to induce cellular apoptosis arises
from Vpr mediated activation of the intrinsic death pathway via cytochrome c and caspase
activation, similar to Env activity [72,76]. Furthermore, a systematic mutation of the open
reading frames (ORFs) of HIV-1 revealed that Vpr, in conjunction with Vif, was able to
induce cell death and G2 cell cycle arrest [73].
Studies have also demonstrated Vpr-induced mitochondrial compromise via damage
to mitochondrial fusion protein mitofusin 2 (Mfn2). Mfn2 critically functions to regulate
mitochondrial functions such as contact with other cellular organelles, trafficking, turnover,
and fusion. Vpr-induced damage to Mfn2 thus alters Mfn2-mediated interactions between
the endoplasmic reticulum (ER) and mitochondria in human peripheral blood mononuclear
cells (PBMCs) (Figure 2). Vpr can localize to the ER, mitochondria-associated membranes
(MAM), and mitochondrial outer membrane (MOM), likely occurring through the integration of the C-terminal transmembrane domain. In addition to disrupting the structural
stability of the MOM, Vpr was also shown to correlate with reduced protein expression
levels of Mfn2 [77]. This level of Vpr-induced repression of Mfn2 corresponds to significant
depletion of mitochondrial activity and is likely involved in the pathogenesis of a wide
range of disease states.
2.4. HIV-Encoded Tat: A Regulator of Apoptosis and DNA Damage Repair
The HIV genome also encodes for the Tat protein, which is known to be produced
in infected cells, followed by release and reuptake into uninfected neighbor cells via
endocytosis (Figure 2). Tat is also capable of triggering apoptosis and taking part in the
bystander effect and infection of neighboring cells through CCR5 and CXCR4 receptors.
Literature suggests that Tat induces apoptosis via regulation of the classical intrinsic
apoptosis pathway. Specifically, Tat can downregulate Bcl-2, an antiapoptotic protein,
and upregulate the proapoptotic caspase-8 to facilitate the release of proapoptotic agent
cytochrome c, as well as proapoptotic FasL and Bax [78]. Literature also shows that Tat
upregulates TNF-related apoptosis-inducing ligand (TRAIL) production in macrophages
(Figure 2) and that T cells from PLHIV are more prone to TRAIL-induced apoptosis [79].
Furthermore, Tat has been shown to mechanistically inhibit the telomerase enzyme.
Telomerase repairs DNA shortening that occurs with continual replication by extending
the hexameric DNA repeats at the ends of chromosomes—telomeres. While telomerase
has been shown to be reduced in CD4 T cells infected with HIV, Tat exposure alone was
able to induce this telomerase reduction. Specifically, Tat can reduce nuclear expression of
the catalytic subunit of telomerase, telomerase reverse transcriptase (hTERT), and disturb
the AKT pathway, which is critical for activation of hTERT [80]. Tat also has been shown
to suppress the transcription of cell cycle regulator p53 [81,82]. These data highlight an
additional mechanism by which Tat is able to damage the replicative potential of both
infected and noninfected CD4 T cells, potentially contributing to the depletion of functional
CD4 T cells in PLHIV. Additionally, some studies have identified a potential molecular
link between telomeric DNA damage and mitochondrial dysfunction via a p53-dependent
pathway [54,83,84]. Collectively, these findings indicate that Tat facilitates mitochondrial
dysfunction via several independent mechanisms.
2.5. HIV-Encoded Nef: A Regulator of Apoptosis and Mitophagy
The virally encoded protein Nef is essential for T cell activation and maintaining
persistent infection [85]. Nef induces TCR-independent activation of T cells and allows for
the infection of neighboring T cells through the CCR5 and CXCR4 receptors, contributing
to bystander-induced apoptosis and depletion of CD4+ T cells. Literature shows that T cells
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expressing Nef also express FasL, enabling these cells to kill uninfected T cells expressing
Fas, indicating that Nef has an additional method to induce bystander apoptosis. Nef also
induces apoptosis via two proapoptotic structural motifs [79].
Moreover, Nef has been shown to regulate the processes of autophagy and mitophagy
(the selective degradation of damaged mitochondria via autophagy). Most commonly,
Nef inhibits autophagy to allow for viral survival by interacting with integral proteins in
autophagy initiation, including Beclin 1 [65,86]. Since autophagy is critical for maintaining
cellular homeostasis and mitochondria are the key energetic supplier, continued inhibition
of autophagy and mitophagy from Nef interactions may lead to disruption of mitochondrial
activity and accumulation of nonfunctional mitochondria [87]. This would further lead to
increased ROS and mitochondrial DNA damage.
2.6. HIV-Mediated Mitochondrial Compromise
Individuals with latent HIV show enrichment of genes regulating cell death, cell
activation, and inflammatory chemokines and cytokines in PBMCs and muscle and adipose
tissues, whereas genes responsible for governing mitochondrial function and biogenesis
were downregulated in both PBMCs and adipose tissues from patients with long-term
controlled HIV viral load [65,88]. Thus infection also has a direct influence on mitochondrial function, activation of immune cells, and inflammation, all of which likely contribute
to the premature aging observed in HIV infection [64,83]. It is important to note that
HIV-induced apoptosis via depolarization of the mitochondrial membrane also contributes
to mitochondrial dysfunction by inducing mtDNA mutations and deregulating OXPHOS,
ATP synthesis, and ROS production [64]. The ∆Ψm is essential to maintaining cell viability
and homeostasis, as evidenced by ∆Ψm disruption, leading to failure to eliminate dysfunctional mitochondria and transport critical ions and proteins required for mitochondrial
activity [33,88].
Additionally, research shows that PLHIV are more likely to show premature aging,
which is linked to increased oxidative stress and damage and shortened telomeres which
could further contribute to mitochondrial and metabolic compromise [52,84,89–92]. A study
investigating mitochondrial function in ART-naïve and ART-exposed PLHIV demonstrated
increased mitochondrial mass in both CD4+ and CD8+ T cells with the loss of CD4+ T
cells. HIV also appeared to target ∆Ψm in CD8+ T cells, leading to ROS accumulation
in CD4+ T cells. Following ART therapy, both cell subsets showed a significant decrease
in mitochondrial mass, followed by an increase after three years of treatment. These
results indicate a dynamic fluctuation in immune cell response to HIV infection and ARTmediated suppression of infection, which was unique between CD4+ and CD8+ T cells [7].
This deregulation of mitochondrial parameters and increased oxidative stress can initiate
a vicious cycle of overproduction of ROS, mtDNA damage, mitochondrial failure, and
apoptosis, further contributing to metabolic compromise during HIV infection.
Interestingly, a study examining the intracellular distribution of HIV-1 RNA in infected
cells revealed significantly increased levels of viral RNA localized in the mitochondria
compared to the cytoplasm and nucleus in the latently HIV-1-infected T cell line ACH2
following TCR stimulation. The level of viral RNA localized in mitochondria of infected
cells was significantly lower in chronically infected cells versus acutely infected cells [93].
Live-cell real-time fluorescence imaging also showed that mitochondria from HIV-infected
H9 cells can be transported into uninfected cells (MT2 target cells) to facilitate viral transmission. Furthermore, culturing uninfected cells in the presence of isolated mitochondria
from HIV-infected T cells resulted in infection, as measured by viral antigen p24 production,
syncytia development, and depletion of target cells, which was prevented by culturing in
the presence of pharmacological inhibitors of mitochondrial function [94]. Mitochondria
from HIV-infected cells can thus function as viral reservoirs to facilitate cell-to-cell infection.
Additionally, a study identified that PLHIV who have self-control of their infection and low
levels of viremia, referred to as long-term nonprogressors (LTNPs), have significantly lower
rates of apoptosis and mitochondrial compromise in PBMCs compared to untreated asymp-
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tomatic typical progressors (TPs) with high viremia and immunological deterioration [95].
These results indicate the existence of a potential conditional influence of mitochondria
in HIV infection, viral latency, and disease severity. Thus, it may be possible that HIV
intentionally hijacks mitochondrial activity to facilitate increased viral transmission and
infectivity at varying levels during different stages of HIV-infection.
The modulation of mitochondrial function may be an ideal approach for the virus
to facilitate infection due to the critical role of mitochondria in innate and antiviral immune responses [96]. To avoid mitochondria-mediated HIV-clearance, HIV likely targets
mitochondrial function via mtDNA copy number depletion and deregulation of ∆Ψm and
mitochondrial signaling. Collectively, the influences from HIV-infection contribute to both
viral infectivity and ultimate mitochondrial compromise. This indicates the presence of
a fine-tuned balance between using mitochondrial for transmission and for inhibiting
immune responses to HIV infection.
2.7. ART-Induced Mitochondrial Dysfunction
While mitochondrial functions are repressed in ART-naïve PLHIV, prolonged exposure to ART has been shown to increase the adverse effects previously thought to only
be associated with HIV infection [21,83,97–105]. In fact, in the era of ART, the impact
of progressive infection is lesser than that of long-lasting ART treatment, especially in
the case of aviremic patients. Classes of ART approved for the treatment of HIV include
nucleoside-analog reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), integrase inhibitors (INIs), which
contains the subclass integrase strand transfer inhibitors (INSTIs), fusion inhibitors, and
coreceptor antagonists, each of which interferes with critical steps in the viral replication
lifecycle. The first generation of approved ART drugs was NRTIs. NRTIs inhibit DNA
polymerase gamma (Pol-γ), which functions in mitochondrial DNA (mtDNA) replication
and maintenance, implicating ART as a potential cause of mitochondrial dysfunction [102].
Alternately, mitochondrial dysfunction is also associated with NNRTIs, PIs, and INSTIs,
despite these drug classes not disrupting Pol-γ activity [71,95,106]. Despite ART treatment
decreasing HIV-associated comorbidities and improving mortality of PLHIV, mitochondrial
functions are disrupted even in clinically stable patients [103].
The administration of combined ART creates an increasingly difficult landscape to
assess the disruption of mitochondrial function by ART regimens individually. Understanding the unique processes by which HIV-infection in combination with ART leads to
mitochondrial dysfunction may allow for the development of improved therapeutics and
quality of life for PLHIV. Considering the prevalence of the inclusion of NRTIs, NNRTIs,
PIs, and INSTIs, as well as the evidence supporting increased adverse effects of these drugs
compared to fusion inhibitors and coreceptor agonists, for the purposes of this review
we hereafter focus on mitochondrial toxicity associated with NRTIs, NNRTIs, PIs, and
INSTIs [107,108]. These results, along with mitochondrial deregulation by all ART classes,
are summarized in Table 1.
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Table 1. Pharmacology of antiretroviral therapy and reported effect on mitochondria [105,109,110].
Drug Class

Mechanism of Action

NRTIs
(Abacavir, Tenofovir)

Prevents viral replication by
inhibiting HIV reverse
transcriptase

NNRTIs
(Rilpivirine, Efavirenz,
Nevirapine)

Prevents viral replication by
noncompetitively binding to
HIV reverse transcriptase

Mitochondrial Dysfunction

Species and Cell Type
Models

Inhibition of Pol-γ [111]
Reduction of mtDNA copy
number/mitochondrial encoded
proteins [106]
Reduced lymphocyte
proliferation Respiratory chain
deficiency Inhibition of ETC
complexes [113]
ATP reduction [30,114]
Increased oxidative stress
Decrease in Ψm [112]

Human fibroblasts [111,112],
PBMCs [106], CD4, and CD8
cells [113], and rat liver
cells [30,114]

Respiratory chain deficiency
ATP reduction
Increased oxidative stress [109]
Decrease in Ψm
Apoptosis [110,115–117]

Human hepatic cells [109],
PBMCs [110,115], coronary
artery endothelial cells [116],
and hepatoma cells [117],
and Jurkat T cell line [115]

Increased oxidative stress [118]

Human CD4, CD8 [64],
macrophage-derived foam
cells [119], endothelial [118],
hepatoma [117], and hepatic
cells [120], and Huh-7.5,
293T, HeLa, and Hepa RG
cell lines [121]

PIs
(Ritonavir, Darunavir,
Atazanavir, Indinavir,
Saquinavir)

Prevents viral replication by
inhibiting HIV protease

Reduced mtDNA copy number
Respiratory chain deficiency
Reduced ATP [64,119]
Apoptosis [119,122,123]

INIs
(Raltegravir, Dolutegravir,
Elvitegravir)

Prevents integration of viral
DNA into the host genome by
inhibiting HIV
integrase enzyme

Respiratory chain deficiency
Increased oxidative stress
Increased cytoplasmic mtDNA
copy number [64]

Human CD4 and CD8 [64]

Fusion Inhibitors
(Leronlimab, Ibalizumab,
Enfuvirtide)

Prevents viral fusion with
target cell membrane by
binding to the viral envelope
protein gp41

Not identified

N/A

Coreceptor Antagonists
(Aplaviroc,
Maraviroc,
Vicriviroc)

Prevent viral infection by
interfering with viral entrance
into the cell by blocking the
coreceptors, such as CCR5 or
CXCR4, on the surface of
target immune cells

Not identified

N/A

Note: NRTIs (nucleoside reverse transcriptase inhibitors), human immunodeficiency virus (HIV), mitochondrial DNA (mtDNA), electron
transport chain (ETC), mitochondrial membrane potential (Ψm ), peripheral blood mononuclear cells (PBMCs), non-nucleoside reverse
transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), integrase inhibitors (INIs).

2.8. NRTIs
Currently, NRTIs are the most common drug class to be incorporated in ART. NRTIs
are incorporated into viral DNA and cause chain termination to disrupt the viral capacity
to complete reverse transcription of viral RNA into DNA (step 3 in Figure 1) [21,95,101,106].
NRTIs may be incorporated into mtDNA via Pol-γ by competing with natural thymidine
triphosphates, ultimately leading to mutations in the chain or termination of mtDNA synthesis [122–126]. However, more recent studies have highlighted additional mechanisms
in NRTI-induced mitochondrial dysfunction [127]. NRTIs have been shown to impair
ATP/ADP translocation through channels, which inhibits the coupling of respiration and
ATP synthesis [30,114]. NRTIs also induce time- and dose-dependent depletion of mtDNA
copy number, lymphocyte proliferation, and cytochrome c-oxidase II expression in primary
CD4+ and CD8+ T lymphocytes from HIV-negative individuals [113]. NRTI treatment has
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also been shown to lead to a significant upregulation of coding region nonsynonymous
substitutions in mtDNA in PLHIV, leading to mitochondrial toxicity, compared to HIVnegative controls. Results revealed significantly increased mtDNA deletion mutations
in the ND4 gene, which codes for NADH dehydrogenase, in treated PLHIV compared
to uninfected healthy subjects [106]. NRTI-induced mitochondrial dysfunction was also
observed to be progressive and continued NRTI-exposure was associated with progressive loss of oxidative respiration in primary human lymphocytes [113]. Furthermore,
mitochondrial function and mtDNA content, along with associated pathologies such as
neuropathy and hyperlactatemia have been shown to recover upon NRTI discontinuation.
Thus, the current recommendation for individuals experiencing mitochondrial toxicity
following NRTI treatment is the discontinuation of the treatment [100,128–130]. These
results indicate that the reduction in mtDNA copy number is significantly linked to the
decline in mitochondrial respiration capabilities. This phenomenon is likely due to mtDNA
copy number reduction initiating ineffective synthesis of OXPHOS proteins, increasing the
level of oxidative stress produced by mitochondria that induce further damage to mtDNA,
proteins, and lipids [127].
NRTIs, but NNRTIs, have also been shown to inhibit telomerase function both in vitro
and in vivo, while also being incorporated into telomeric DNA, leading to chain termination
and often cell death [131]. Furthermore, Pol-γ has also been shown to be sensitive to
oxidative stress [111]. Together, these data represent a molecular cycle in which mtDNA
mutations, which may be increased due to the high processivity of Pol-γ and ART exposure,
lead to energetic deprivation and mitochondrial dysfunction, inducing mitochondrial
function failure and increased oxidative stress. ROS are then able to induce further mtDNA
damage and impair mtDNA replication. By this mechanism, the level of mtDNA mutations
will continue increasing and may lead to a progressive system of increasing symptoms.
Interestingly, a study identified that HAART-treated PLHIV had significantly higher serum
oxidant levels and reduced serum antioxidant makers compared to both untreated PLHIV
and uninfected controls. Furthermore, this level of increased oxidative stress was directly
correlated with the level of HAART treatment adherence [132]. While this does not directly
implicate NRTIs alone (all individuals were on various forms of combined HAART, but all
included at least one NRTI), it highlights a critical role HIV-treatments in inducing oxidative
stress in ART-treated individuals. Collectively, these data suggest that mitochondrial
toxicity induced by NRTI treatment may arise due to the deregulation of the mitochondrial
network, mtDNA mutations, and oxidative stress.
2.9. NNRTIs
NNRTIs inhibit reverse transcription of the virus via binding to a hydrophobic pocket
adjacent to the active site of HIV reverse transcriptase (step 3 in Figure 1) [21,95,101,106].
The most common NNRTI is efavirenz (EFV), which is particularly successful in inhibiting
viral replication. However, EFV is correlated with reduced cell growth and increased
apoptosis, oxidative stress, mitochondrial mass, and mitochondrial protein expression in
Hep3B hepatic cells. Several of these results were obtained even after short incubation
times with EFV. This indicates the likelihood that these modifications are not directly linked
to mtDNA replication, due to the short incubation times and lack of change in mtDNA copy
number. Additionally, the disruption to mitochondrial function was rescued by treatment
with antioxidant Trolox, highlighting the critical role of ROS in generating mitochondrial
compromise [109]. EFV is also toxic to hepatocytes and human coronary artery endothelial
cells and disrupts the ∆Ψm , leading to cytochrome c release and apoptosis [116,117]. Both
CD4+ and CD8+ T cells show decreased levels of activation markers after NNRTI treatment,
indicating a weakening of the immune system and ability to mount an immune response
after NNRTI treatment [133].
A study in Jurkat cells evaluating the effects of exposure to the NRTI zidovudine (AZT)
or the NNRTI EFV revealed that EFV, but not AZT, significantly upregulated apoptosis, the
release of cytochrome c, and reduced ∆Ψm in a dose- and time-dependent manner [110].
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Importantly, while the evaluation of mitochondrial alterations induced by other NNRTIs,
such as nevirapine (NVP), does not align linearly with the results obtained for EFV, NVP has
been shown to induce apoptosis via deregulation of ∆Ψm in lymphocytes from PLHIV [115].
Collectively, these data indicate that while different NNRTIs may not induce the same types
of mitochondrial dysfunction based solely on their mechanism of action, these drugs can
still induce differential regulation of various mitochondrial functions and cellular stress.
2.10. PIs
In addition to NRTIs and NNRTIs, another common drug class included in HAART
are PIs. PIs interfere with the cleavage of essential viral maturation polyprotein precursors,
including gag and pol by inhibiting the HIV protease (step 10 in Figure 1) [21,95,101,106].
There is a significant amount of data supporting the role of PIs in inducing oxidative stress
among a large number of cell types and model systems, ultimately leading to the main
side effects associated with PIs, including cardiovascular disease and lipodystrophy, which
have been reviewed elsewhere [118,122]. Monotherapy of CD4 T cells with the PI ritonavir
led to increased mtDNA copy numbers in CD4+ T cells, increased ROS, and an interruption
to ∆Ψm and thus ETC and OXPHOS capacity [64]. Furthermore, ritonavir treatment
decreased ∆Ψm , increased NADPH oxidase subunits, increased oxidative stress, decreased
ATP production, and deregulated MAPK ERK1/2 activity in macrophage-derived foam
cells [119]. Ritonavir treatment of Huh-7.5 (human hepatoma cells) showed increased
ER stress even after only 6 h of exposure. This ER stress also triggered the translocation
of BAX to mitochondria to initiate apoptosis independently of mitochondria (there was
no change in mitochondrial potential or release of cytochrome c). Additionally, it was
confirmed that both EFV and ritonavir were able to enter the mitochondria and lead to
a reduction of the ∆Ψm , leading to BAX translocation and cytochrome c and ultimately
apoptosis [119,122,123]. PIs are also tightly correlated with metabolic disruption of lipid
metabolism and glucose transport, which are also controlled by mitochondria [134,135].
Another PI implicated in mitochondrial dysfunction is atazanavir, which was shown to
induce autophagy, apoptosis, mitochondrial superoxide generation, and depolarization of
the membrane potential, while ritonavir caused apoptosis but low rates of autophagy in
preadipocytes [136].
PIs have also been identified to induce cell death in PBMCs from uninfected individuals. While some studies have shown decreased apoptosis in HIV-infected and uninfected T
cells following treatment with PIs [137,138], another study evaluating T-cell proliferation
and cell death following exposure of T cells from healthy individuals to PIs indinavir (IDV)
and saquinavir (SQV) revealed decreased proliferation, reduced ∆Ψm , and increased CD4
T cell death [139]. Conversely, PIs have also been shown to inhibit apoptotic pathways
in HIV infected T cells, specifically by inhibiting apoptosis induced by gp120; however,
PIs also contribute to a disrupted mitochondrial membrane and induce necrosis [102,140].
These data indicate that PIs may demonstrate both advantageous and detrimental effects
in a cell- and tissue-dependent manner.
2.11. INSTIs
INSTIs have become a widely used ART formulation. INSTIs inhibit DNA strand transfer,
during which the viral DNA ends are joined into host DNA (step 5 in Figure 1) [21,95,101,106].
In recent years, the most common first-line approach for the treatment of naïve PLHIV has
become the administration of an INSTI with NRTIs [101,141]. While extensive research has
not yet been completed to identify the potential deregulation of mitochondria by INSTIs, a
recent study assessing metabolic and cellular activity in immune cells from treated PLHIV
and HIV-negative controls revealed that ART was able to restore the metabolic profile of B
cells, NK cells, and CD8+ T cells, but not in CD4+ T cells. Furthermore, CD4 T cells showed
a more severe shut down in cellular respiration and a shift to glycolysis from OXPHOS.
This was more prevalent in cells from individuals treated with the INSTI dolutegravir
(DLG) in triple therapy, compared to non-INSTI ART regimens. Additionally, a comparison
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of the ex vivo proliferation of CD4+ T cells demonstrated repressed proliferation in CD4 T
cells from individuals on treatment with INSTIs versus NNRTI- or PI-regimens. Further
evaluation of the effect of INSTIs was completed by treating CD4 T cells from uninfected
individuals. Both DLG and elvitegravir (EVG), but not raltegravir (RAL), showed significantly decreased cellular respiration in a dose-dependent manner but did not affect
∆Ψm or cellular cytotoxicity. Both drugs induced increased mtDNA copy number and
ROS levels, implicating INSTIs as a deregulator of mitochondrial function and immune
cell metabolism [64]. While this study highlights potential mitochondrial deregulation by
INSTIs, further research is still needed to validate the influence of INSTIs on mitochondria.
Holistically, these findings suggest that regardless of the class of ART treatment, PLHIV using these regimens are at a greater risk of developing premature aging associated
with mitochondrial dysfunction, many of which are progressive in nature as treatment time
is prolonged. This presents a significant limitation with respect to current HIV treatments
due to the need for lifelong treatment adherence. Additionally, the current literature lacks
clear evidence for the differential roles of drugs and the relationship between drug mechanism of action and mitochondrial failure due to the profound use of combined HAART.
This makes it increasingly difficult to assess and identify mitochondrial deregulation from
these drugs independent of additional pharmacological influences.
3. Discussion
While ART has transformed the HIV/AIDS global epidemic into a well-controlled
chronic disease, PLHIV still demonstrate a wide variety of metabolic and immunological failure phenotypes, contributing to increased morbidity and mortality as well as
lower patient quality of life and accelerated aging. As shown in Figure 2, both HIV and
ART induce a multitude of injuries to mitochondrial function, including deregulation of
ETC respiration and ATP synthesis, mtDNA damage, disruption of ∆Ψm , and increased
oxidative stress. Upon increased oxidative stress, further mtDNA mutations occur, leading to HIV/ART-induced activation of a cycle of continued mtDNA damage, impaired
mitochondrial function, increased oxidative stress, and impaired ATP production and
cellular homeostasis.
It is thus important to note the mechanisms of mtDNA maintenance and the process of
accumulating deleted mtDNA content. Unlike nuclear DNA, mtDNA synthesis occurs in a
continual cycle independent of cellular division. HIV and ART regimens are able to disrupt
Pol-γ, which works to form the mtDNA replisome along with several critical enzymes,
including Twinkle, mitochondrial topoisomerase I, mitochondrial RNA polymerase, RNase
H1, and mitochondrial genome maintenance exonuclease 1. Along with these enzymes,
mtDNA synthesis also requires equilibrium of deoxyribonucleotide triphosphates (dNTPs)
via either de novo or salvage mechanisms, many of which involve mitochondrial transport
pathways. Thus, disruption to a step in mtDNA maintenance will lead to the accumulation
of damaged mtDNA content. This process has been shown to contribute to the physiological aging process, as many of the critical effector proteins in mtDNA synthesis and repair
(including BER) become disrupted or weakened with aging [142–144]. In addition to mitochondrial deregulation from mtDNA mutations and damage, telomeres, which serve as a
genomic readout of aging, are also sensitive to HIV/ART-induced DNA damage, which
could propagate mitochondrial dysfunction via telomere, p53, and PGC (master mitochondrial regulator) interactions in individuals on prolonged ART therapies [7,51,54,83,84].
Thus, p53 activation, telomere erosions, and mitochondrial dysfunction have been identified as a potential “axis of aging” that may illuminate an underlying mechanism by which
aging promotes cellular dysfunction and disease progression.
Another critical factor to consider is the influence of heteroplasmy, since human cells
have multiple organellar genomes, arising from both mitochondrial and nuclear-encoded
genes. It is well understood that a certain level of mitochondrial mutations are always
present at low levels but typically only cause physiological changes in the event that
the mutations accumulate over time and reach a threshold at which the ratio of mutated
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mtDNA versus wild-type mtDNA is sufficient (typically >80%) to cause a disruption to the
respiratory chain [142,145]. The presence of heteroplasmy likely plays a critical role in the
level of mitochondrial dysfunction required to cause physiological problems.
Mitochondrial processes are also affected by virally encoded proteins that serve to
deregulate cell metabolism and apoptosis via disruption of the cell apoptotic signals. HIVproteins may use inhibiting apoptosis as a means to delay premature cell death to facilitate
viral persistence. This process is likely mediated by the progression of HIV and the viral
lifecycle. For instance, virally encoded proteins are more likely to be antiapoptotic during
acute infection to enable persistent infection but may transition to being proapoptotic in
the process of establishing chronic infection [14]. This hypothesis may provide insights into
the progressive decline across a wide range of cellular contexts in PLHIV on ART [7,67,83].
A clinical feature of HIV infection is the chronic activation of the immune system
and inflammation. Several HIV proteins induce activation of the immune system and
while ART reduces the level of immune activation, it does not restore it to that observed in
uninfected individuals. Furthermore, the role of ART in the differential effects of immune
activation and inflammation is still unclear [146,147]. Interestingly, mitochondrial function
has been shown to be critically linked to the activation, proliferation, survival, and effector
status of T cells. Specifically, mice with a T-cell specific reduction of a mitochondrial
complex III subunit showed normal T cell proliferation ability but a significantly reduced
level of mitochondrial ROS production, which inhibited the antigen-specific expansion
of T cells [148]. These data implicate mitochondrial ROS signaling in the regulation of T
cell activation, indicating a potential molecular link between mitochondrial metabolism
and immune activation. Furthermore, evidence suggests that HIV uses mitochondria as an
additional reservoir to facilitate infection to new target cells [94].
Aging occurs due to the accumulation of cellular injuries, ultimately leading to disrupted cellular homeostasis, increased oxidative stress, and cellular senescence. A significant amount of evidence is present in the literature linking the degenerative aging
process to deregulated mitochondrial function [51,65,149]. Specifically, deregulation of mitochondrial respiration, ATP production, and cell apoptosis contribute to progressive loss
of cellular homeostasis. Evidence supports the notion of increased incidence of metabolic
disorders and mitochondrial failure with increased age, which have been proposed to
underlie the loss of vigor in the elderly [149–153]. The model of increased oxidative stress
inducing mtDNA mutations is a central mechanism commonly used to explain the aging
phenomenon. Furthermore, the expression of critical proteins involved in mitochondrial
biogenesis and mtDNA maintenance, including PGC-1α, ERR-α, NRF-1, and TFAM are
significantly downregulated in aging cells or tissues [144,154–157]. Interestingly, age-linked
associations have been made across a wide range of chronic viral infections, including but
not limited to HIV, HCV, HBV, and CMV, as evidenced by increased telomere erosion and
telomeric DNA damage, mitochondrial dysfunction, and cellular senescence [43,57,158–160].
Currently, there is conflicting evidence regarding the role of senescence in viral infection, primarily due to some new data implicating senescence in host antiviral defense
via inhibiting viral replication, attracting innate immune cells, and activating cytokine
signaling. Alternately, several investigations have shown that senescence is involved in
the pathophysiology of viral infections via enhancing viral replication and suppressing
antiviral type I IFN activation [160]. For example, RSV can cause DNA damage-induced
senescence in lung epithelial and mononuclear cells in mice, ultimately leading to airway
tissue remodeling and permanent tissue damage [58]. Additionally, influenza and herpes
viruses have been shown to have increased viral replication in senescent cells [160–162].
Thus, it is likely that the dual role of senescence in virology is virus- and tissue-specific.
Recently, aging, along with mitochondrial dysfunction, has demonstrated a correlation
with disease outcome in individuals infected with SARS-CoV-2, the virus responsible for
the current COVID-19 worldwide pandemic [163]. One study using an RNA–GPS method
predicted that SARS-CoV-2 RNA localized to mitochondria, similar to that observed for HIV,
indicating a possible shared mechanism between these viruses in which mitochondria are
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central to viral infection [164]. Intriguingly, senescence has also been shown to play a role
in the severity/death/pathogenesis of COVID-19 as aged individuals have approximately
a 20% higher mortality rate than younger individuals when infected with SARS-CoV-2,
likely due to the role of senescence in immune cells (immunosenescence) [160,165]. Cellular
senescence is also critically influenced by mitochondrial dysfunction, as evidenced by the
presence of impaired mitochondria and shortened telomeres (both of which are impacted
by HIV infection and ART treatment) [46,166]. This indicates the likelihood that a variety
of viral infections use metabolic and mitochondrial deregulation to instigate accelerated
telomeric DNA damage, aging, and cellular senescence.
A recent study examined the potential cellular effects of ART as preventative preexposure prophylaxis (PrEP) for healthy individuals. PBMCs from individuals treated
with PrEP showed reduced cellular respiration and mitochondrial mass. Additionally,
monocyte-derived macrophages from PrEP-treated individuals exhibited increased production of ROS and decreased mitochondrial mass, further implicating ART in inducing
mitochondrial dysfunction even in the absence of HIV infection [167]. This is of particular importance considering the target populations that are not HIV-infected but have
an increased predisposition to HIV, including individuals using PrEP as well as children
of infected mothers receiving PrEP as part of prevention of mother to child transmission
programs. Interestingly, discontinuation of HAART has been shown to restore mtDNA
copy number, implying a direct role of treatment in mitochondrial compromise [129].
More recent studies have highlighted the potential improvement of mitochondrial
toxicity associated with newer formulations, including INSTIs, fusion inhibitors, and
coreceptor antagonists [108]; however, more extensive studies need to be completed to
identify if these drugs and their combined regimens also reduce the likelihood of inducing
mitochondrial compromise. Additionally, current research lacks definitive evidence of
the level of deregulation due to either ART or HIV alone since most research examines
healthy controls, ART-naïve PLHIV, and ART-treated PLHIV, limiting the information
obtained regarding ART treatment outside the context of HIV infection. Furthermore,
given the overwhelming use of combined therapy, it is difficult to critically assess the
differential roles of ART regimens. This review highlights various mechanisms by which
both HIV-encoded proteins and ART treatments damage critical mitochondrial functions;
however, a multitude of other mechanisms have been studied but are not mentioned here
for brevity [14,68,69,85,107].
While advancements concerning ART treatments have provided a wide range of
potential therapeutics to PLHIV, it is still critical to examine the mechanisms by which
antiretroviral therapies may lead to a progressive decline in cellular functions. This is
particularly necessary in the case of PLHIV, who must maintain strict lifelong treatment
adherence to prevent viral rebound [109]. Mitochondrial dysfunction induced by both HIV
infection and continued ART treatment leads to diverse associated pathologies and potential comorbidities in PLHIV (Figure 3). Having a clearer understanding of the mechanisms
by which HIV and ART treatment contribute to mitochondrial dysfunction independently
and potentially in a cooperative manner may allow for the improvement of treatment
regimens, and a better understanding of disease pathologies associated with immune
dysregulated PLHIV.
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